ELOXX PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 63.92% for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2013-03-31 was 97.00%, a 6.73% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2012-12-31 was 102.00%, a 1.92% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2012-03-31 was 104.00%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2011-12-31 was 104.00%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 82.00%, a 6.49% increase from fiscal 2021.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2021 was 77.00%, a 3.75% decline from fiscal 2020.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2020 was 80.00%, a 13.04% decline from fiscal 2019.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2019 was 92.00%, a 0.00% change from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 63.92% S-1 · filed 2026-09-11 | ||||
| 2023-12-31 | 86.95% S-1 · filed 2026-09-11 | ||||
| 2022-12-31 | 82.00% 10-K · filed 2023-03-31 | ||||
| 2021-12-31 | 77.00% 10-K · filed 2023-03-31 | ||||
| 2020-12-31 | 80.00% 10-K · filed 2023-03-31 | ||||
| 2019-12-31 | 92.00% 10-K · filed 2023-03-31 | ||||
| 2018-12-31 | 92.00% 10-K · filed 2021-03-12 | ||||
| 2017-12-31 | 117.00% 10-K · filed 2020-03-06 | 116.69% 10-K · filed 2018-03-16 | |||
| 2016-12-31 | 105.57% 10-K · filed 2019-03-14 | ||||
| 2016-06-30 | 146.00% 10-K · filed 2017-10-13 | ||||
| 2015-12-31 | 88.72% 10-K · filed 2018-03-16 | ||||
| 2015-06-30 | 153.00% 10-K · filed 2017-10-13 | ||||
| 2014-06-30 | 99.00% 10-K · filed 2016-10-13 | ||||
| 2013-06-30 | 102.00% 10-K · filed 2015-10-09 | ||||
| 2013-03-31 | 97.00% 10-Q · filed 2013-05-15 | 102.00% 10-Q · filed 2013-05-15 | |||
| 2012-12-31 | 102.00% 10-Q · filed 2013-02-14 | 102.00% 10-Q · filed 2013-02-14 | |||
| 2012-06-30 | 105.00% 10-K · filed 2014-09-29 | ||||
| 2012-03-31 | 104.00% 10-Q · filed 2013-05-15 | 105.00% 10-Q · filed 2013-05-15 | |||
| 2011-12-31 | 104.00% 10-Q · filed 2013-02-14 | 105.00% 10-Q · filed 2013-02-14 | |||
| 2011-09-30 | 105.00% 10-Q · filed 2012-11-14 | ||||
| 2011-06-30 | 104.00% 10-K · filed 2013-09-11 | ||||
| 2010-06-30 | 106.00% 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |